Skip to main content

Table 5 The most common (≥ 10%) TEAEs in the safety analysis set

From: A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma

  Ixazomib  + 
LenDex
N = 34
n (%)
Patients with at least 1 AE 34 (100)
Constipation 17 (50)
Upper respiratory tract infection 16 (47)
Diarrhea 14 (41)
Rash 12 (35)
Nasopharyngitis 11 (32)
Nausea 10 (29)
Platelet count decreased 9 (26)
Influenza 8 (24)
Neutropenia 8 (24)
Chilblains 7 (21)
Dysgeusia 7 (21)
Fall 7 (21)
Peripheral sensory neuropathy 7 (21)
Bronchitis 6 (18)
Neutrophil count decreased 6 (18)
Dental caries 5 (15)
Malaise 5 (15)
Edema peripheral 5 (15)
Pharyngitis 5 (15)
Maculopapular rash 5 (15)
Vomiting 5 (15)
Back pain 4 (12)
Dry skin 4 (12)
Hyperglycemia 4 (12)
Oropharyngeal pain 4 (12)
Pain in extremity 4 (12)
Pneumonia 4 (12)
Pyrexia 4 (12)
Stomatitis 4 (12)
Thrombocytopenia 4 (12)
Urticaria 4 (12)
  1. AE adverse event, LenDex lenalidomide and dexamethasone, TEAE treatment-emergent adverse event